Literature DB >> 29268452

Natriuretic peptide-guided versus clinically guided therapy for chronic heart failure: careful expert clinical management can remove need for biomarker-tailored dosing adjustment.

Renato De Vecchis1.   

Abstract

Entities:  

Year:  2017        PMID： 29268452      PMCID： PMC5720960          DOI： 10.21037/jtd.2017.10.26

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  12 in total

1.  Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations.

Authors:  R W Troughton; C M Frampton; T G Yandle; E A Espiner; M G Nicholls; A M Richards
Journal:  Lancet       Date:  2000-04-01       Impact factor: 79.321

2.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.

Authors:  Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Mark H Drazner; Gregg C Fonarow; Stephen A Geraci; Tamara Horwich; James L Januzzi; Maryl R Johnson; Edward K Kasper; Wayne C Levy; Frederick A Masoudi; Patrick E McBride; John J V McMurray; Judith E Mitchell; Pamela N Peterson; Barbara Riegel; Flora Sam; Lynne W Stevenson; W H Wilson Tang; Emily J Tsai; Bruce L Wilkoff
Journal:  Circulation       Date:  2013-06-05       Impact factor: 29.690

Review 3.  The predictive value of plasma biomarkers in discharged heart failure patients: the role of plasma BNP.

Authors:  Matteo Beltrami; Alberto Palazzuoli; Gaetano Ruocco; Nadia Aspromonte
Journal:  Minerva Cardioangiol       Date:  2015-10-16       Impact factor: 1.347

4.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

Authors:  Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer
Journal:  Eur J Heart Fail       Date:  2016-05-20       Impact factor: 15.534

5.  Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.

Authors:  G Michael Felker; Kevin J Anstrom; Kirkwood F Adams; Justin A Ezekowitz; Mona Fiuzat; Nancy Houston-Miller; James L Januzzi; Daniel B Mark; Ileana L Piña; Gayle Passmore; David J Whellan; Hongqiu Yang; Lawton S Cooper; Eric S Leifer; Patrice Desvigne-Nickens; Christopher M O'Connor
Journal:  JAMA       Date:  2017-08-22       Impact factor: 56.272

6.  N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial.

Authors:  John G Lainchbury; Richard W Troughton; Kim M Strangman; Christopher M Frampton; Anna Pilbrow; Timothy G Yandle; Amjad K Hamid; M Gary Nicholls; A Mark Richards
Journal:  J Am Coll Cardiol       Date:  2009-12-29       Impact factor: 24.094

7.  Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study.

Authors:  Luc W M Eurlings; Petra E J van Pol; Wouter E Kok; Sandra van Wijk; Cara Lodewijks-van der Bolt; Aggie H M M Balk; Dirk J A Lok; Harry J G M Crijns; Dave J W van Kraaij; Nicolaas de Jonge; Joan G Meeder; Martin Prins; Yigal M Pinto
Journal:  J Am Coll Cardiol       Date:  2010-12-14       Impact factor: 24.094

8.  BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial.

Authors:  Matthias Pfisterer; Peter Buser; Hans Rickli; Marc Gutmann; Paul Erne; Peter Rickenbacher; André Vuillomenet; Urs Jeker; Paul Dubach; Hansjürg Beer; Se-Il Yoon; Thomas Suter; Hans H Osterhues; Michael M Schieber; Patrick Hilti; Ruth Schindler; Hans-Peter Brunner-La Rocca
Journal:  JAMA       Date:  2009-01-28       Impact factor: 56.272

9.  Heart failure outcomes and benefits of NT-proBNP-guided management in the elderly: results from the prospective, randomized ProBNP outpatient tailored chronic heart failure therapy (PROTECT) study.

Authors:  Hanna K Gaggin; Asim A Mohammed; Anju Bhardwaj; Shafiq U Rehman; Shawn A Gregory; Rory B Weiner; Aaron L Baggish; Stephanie A Moore; Marc J Semigran; James L Januzzi
Journal:  J Card Fail       Date:  2012-06-19       Impact factor: 5.712

10.  An Admission-to-Discharge BNP Increase Is a Predictor of Six-Month All-Cause Death in ADHF Patients: Inferences from Multivariate Analysis Including Admission BNP and Various Clinical Measures of Congestion.

Authors:  Renato De Vecchis; Carmelina Ariano; Cesare Baldi
Journal:  J Clin Med       Date:  2016-11-10       Impact factor: 4.241
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.